ABSTRACT
Introduction Despite having the world’s largest HIV epidemic, Sub-Saharan Africa (SSA) including South Africa (SA) has not yet achieved the 95-95-95 targets. To meet these targets, accurate and reliable key populations (KPs) disaggregated data is critical for guiding the HIV response. The inclusion of KPs Unique Identifier Code (UIC) on country’s routine health information management systems (RHIMS) can improve targeted resource allocation, reporting, and accountability. There is a gap in comprehensive review on how countries that implemented the unique identifier code went about in doing so.
Methods and analysis A three-step search strategy will be utilized to get both published and unpublished documents. First, an initial search of MEDLINE identified keywords and MeSH terms. Second, a systematic search of electronic bibliographic databases including MEDLINE, PubMed, Scopus, PLOS ONE and Google Scholar, and thirdly, searching the reference list of all included reviews (hand-searching journals and reference tracking). Studies that meet the following PICO (Population, Intervention, Comparison, Outcome) criteria will be included: P: Published and unpublished materials reporting on key populations, namely men who have sex with men (MSM), sex workers (SW), people who inject/use drugs (PWI/UD), and transgender (TG); I: biometric fingerprint, alphanumeric code and any KPs UIC system; C: no unique identifier system; and O: KPs-specific 95-95-95 HIV cascade, KPs knowing HIV status, KPs on ART, ART adherence and Viral load suppression. This protocol was prepared using the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). References will be managed through ENDNOTE version 21 software. Two authors will screen the studies using Covidence software version 2.0 for inclusion according to the prescribed eligibility criteria. Differences will be addressed by consensus and with the assistance of an experienced third reviewer.
Ethics and dissemination This review will summarize findings from published studies containing non-identifiable data. The results will be disseminated via preprints, open-access peer-reviewed journals, and conference presentations.
PROSPERO registration number CRD42023440656
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be made available upon request made to the corresponding author
